SLC5A2 and prostate carcinoma: In patients with prostate cancer undergoing hormone therapy, the use of SGLT2 inhibitors was associated with significantly reduced all-cause mortality as well as lower risks of heart failure, HF exacerbations, peripheral artery disease, atrial fibrillation, cardiac arrest, and the need for renal replacement therapy.